Report cover image

Clinical Trials Sector Scorecard, Q2 2022 Update - Thematic Research

Publisher GlobalData
Published Jun 30, 2022
Length 18 Pages
SKU # GBDT17363734

Description

Clinical Trials Sector Scorecard, Q2 2022 Update - Thematic Research

Summary

The Virtual Care Landscape Saw Activity in Q2 2022: In Q2 2022, there was increased activity in the virtual care space. Compared to Q1 2022, Novo Nordisk initiated more trials with virtual components and also posted more jobs related to virtual care. Daiichi Sankyo and Takeda are planning a study in Japan that will look at the feasibility of using a wearable device to track lifestyle habits. In May, Pfizer acquired ResApp Health, a digital health company developing smartphone apps for the diagnosis and management of respiratory disease, and Roche partnered with Kaiku Health to offer cancer symptom management and support to clinics and patients via a digital platform.

Companies Were Also Active in ESG Initiatives and Continued to Partner with AI Vendors: In Q2 2022, several companies announced ESG initiatives. This included the announcement that Merck KGaA was going to invest in sites around the world with a focus on water consumption, waste management, and energy efficiency. Sanofi also announced several social initiatives, including the successful pricing of its first bond linked on improving access to essential medicine, the launch of its Diversity, Equity & Inclusion (DE&I) board, and the launch of Foundation S - The Sanofi Collective, its philanthropic endowment fund. In Q2 2022, pharma companies continued to partner with AI vendors like PathAI, VantAI, Standigm, and Owkin.

Scope
  • GlobalData’s Clinical Trials Thematic Scorecard report provides a top-down, comprehensive future outlook for key players in the clinical trial sector over the next two to four years.
  • These themes are Virtual Care, Rare Disease, Orphan Designated Drugs, Strategic Alliances, Real-world Evidence, AI, ESG, Cybersecurity, Cloud Computing, and Blockchain.
  • The scorecard includes 53 companies from across the industry, including biopharmaceutical companies, biosimilar and generic manufacturers, contract development and manufacturing organizations (CDMOs), and contract research organizations (CROs).
  • It is important to note that this scorecard is not an assessment of current performance of a company in a theme, but a view of future performance based on current levels of activity and investment.
  • The methodology section contains information on what data sources were used to generate the thematic scores for each company.
  • The scorecard is live on the PIC and will be updated quarterly.
Reasons to Buy
  • Identify the key clinical trial themes for the next 2-4 years and learn how they will impact the market.
  • Understand which key themes should be addressed to drive share price.
  • Understand which companies are best positioned for success within critical themes and why.
  • Learn which companies have underinvested in key themes and are most vulnerable to disruption.
  • Help companies adapt their strategy to anticipate and benefit from these themes as they play out.
  • Help identify future winners and losers in drug development to inform partnership strategies.

Table of Contents

18 Pages
  • Executive Summary
    • Pharma Theme Map
    • Clinical Trials Scorecard: Key Q2 2022 Updates
    • Company Screen
    • Thematic Screen
    • Valuation Screen
    • Risk Screen
    • Figure 6: Our five-step approach for generating a sector scorecard
    • How Are Our Pharma Scores Generated?
  • Related Reports
    • Senior Director, Thematic Analysis
    • Global Head and EVP of Healthcare Operations and Strategy
  • About GlobalData
  • Contact Us

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us